MA43409B1 - Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton - Google Patents

Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton

Info

Publication number
MA43409B1
MA43409B1 MA43409A MA43409A MA43409B1 MA 43409 B1 MA43409 B1 MA 43409B1 MA 43409 A MA43409 A MA 43409A MA 43409 A MA43409 A MA 43409A MA 43409 B1 MA43409 B1 MA 43409B1
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
tyrosine kinase
polycyclic compounds
bruton tyrosine
compounds
Prior art date
Application number
MA43409A
Other languages
English (en)
Inventor
Nidhi Arora
Genesis M Bacani
Joseph Kent Barbay
Scott D Bembenek
Min Cai
Wei Chen
Charlotte Pooley Deckhut
James P Edwards
Brahmananda Ghosh
Kevin Kreutter
Gang Li
Mark S Tichenor
Jennifer D Venable
Jianmei Wei
John J M Wiener
Yao Wu
Kun Xiao
Feihuang Zhang
Yaoping Zhu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA43409B1 publication Critical patent/MA43409B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La présente invention concerne des composés de formule (i) à utiliser en tant qu'inhibiteurs de kinase de bruton et leur préparation, ainsi que des compositions comprenant lesdits composés.
MA43409A 2015-12-10 2016-12-09 Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton MA43409B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10
PCT/US2016/065954 WO2017100662A1 (fr) 2015-12-10 2016-12-09 Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
MA43409B1 true MA43409B1 (fr) 2020-10-28

Family

ID=57681784

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43409A MA43409B1 (fr) 2015-12-10 2016-12-09 Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA053110A MA53110A (fr) 2015-12-10 2016-12-09 Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA053110A MA53110A (fr) 2015-12-10 2016-12-09 Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton

Country Status (29)

Country Link
US (4) US10717745B2 (fr)
EP (2) EP3719022A1 (fr)
JP (2) JP6835846B2 (fr)
KR (1) KR102103395B1 (fr)
CN (2) CN113121562B (fr)
AR (1) AR107042A1 (fr)
AU (1) AU2016366541B2 (fr)
BR (1) BR112018011526B1 (fr)
CA (1) CA3007990C (fr)
CY (1) CY1123263T1 (fr)
DK (1) DK3386991T3 (fr)
EA (1) EA035168B1 (fr)
ES (1) ES2805835T3 (fr)
HR (1) HRP20201193T1 (fr)
HU (1) HUE049502T2 (fr)
IL (1) IL259863B (fr)
JO (1) JO3794B1 (fr)
LT (1) LT3386991T (fr)
MA (2) MA43409B1 (fr)
MD (1) MD3386991T2 (fr)
ME (1) ME03803B (fr)
MX (1) MX2018007075A (fr)
PL (1) PL3386991T3 (fr)
PT (1) PT3386991T (fr)
RS (1) RS60604B1 (fr)
SI (1) SI3386991T1 (fr)
TW (1) TWI729047B (fr)
UY (1) UY37015A (fr)
WO (1) WO2017100662A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
US20200079790A1 (en) * 2017-03-15 2020-03-12 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
MA52780A (fr) 2018-06-11 2021-04-14 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
CN114945576B (zh) 2020-01-07 2023-10-13 南京明德新药研发有限公司 氘代噻吩并吡啶类化合物
CN117320720A (zh) 2021-03-03 2023-12-29 詹森药业有限公司 使用malt1抑制剂和btk抑制剂的组合疗法
KR20240019214A (ko) 2021-06-04 2024-02-14 얀센 파마슈티카 엔브이 브루톤 티로신 키나제의 억제제 및 이의 사용 방법
CA3223610A1 (fr) 2021-06-30 2023-01-05 Janssen Pharmaceutica Nv Inhibiteurs de la tyrosine kinase de bruton et leurs procedes d'utilisation
CA3227033A1 (fr) 2021-08-09 2023-02-16 Eric Frederik ELDERING Compositions destinees a etre utilisees dans le traitement de malignites des lymphocytes b
WO2023156599A1 (fr) * 2022-02-18 2023-08-24 Janssen Pharmaceutica Nv Synthèse d'inhibiteurs de la tyrosine kinase de bruton

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
CN101056639A (zh) 2004-09-15 2007-10-17 詹森药业有限公司 噻唑并吡啶激酶抑制剂
WO2006118749A1 (fr) * 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Inhibiteurs de la thia-tetraazaacenaphtylene kinase
AU2006278627B2 (en) 2005-08-08 2011-08-18 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
WO2007092879A2 (fr) 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Inhibiteurs de kinase thiatriazaacénaphthylène-6-carbonirile substitués
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
US8598174B2 (en) * 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
WO2011024869A1 (fr) * 2009-08-26 2011-03-03 武田薬品工業株式会社 Dérivé à noyaux hétérocycliques fusionnés et son utilisation
WO2011133609A2 (fr) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Méthodes et nécessaires de prédiction de résultat thérapeutique associée à l'utilisation d'inhibiteurs de la btk
US20140249105A1 (en) 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
MY194905A (en) 2013-03-15 2022-12-22 Janssen Pharmaceutica Nv Processes and Intermediates for Preparing a Medicament
JP6431914B2 (ja) * 2013-12-11 2018-11-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103058A1 (fr) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation
WO2018103060A1 (fr) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation

Also Published As

Publication number Publication date
RS60604B1 (sr) 2020-08-31
LT3386991T (lt) 2020-08-25
DK3386991T3 (da) 2020-07-13
AU2016366541A1 (en) 2018-05-31
SI3386991T1 (sl) 2020-08-31
AU2016366541B2 (en) 2021-05-13
BR112018011526B1 (pt) 2024-02-27
JP2018536686A (ja) 2018-12-13
EP3386991A1 (fr) 2018-10-17
CN113121562A (zh) 2021-07-16
EA035168B1 (ru) 2020-05-08
HUE049502T2 (hu) 2020-09-28
NZ742484A (en) 2021-09-24
CN108884106A (zh) 2018-11-23
KR20180093974A (ko) 2018-08-22
EP3719022A1 (fr) 2020-10-07
MA53110A (fr) 2021-05-12
JP2021073286A (ja) 2021-05-13
TW201734021A (zh) 2017-10-01
JO3794B1 (ar) 2021-01-31
TWI729047B (zh) 2021-06-01
JP7072690B2 (ja) 2022-05-20
BR112018011526A2 (pt) 2018-11-21
US10934310B2 (en) 2021-03-02
EA201891378A1 (ru) 2018-12-28
PL3386991T3 (pl) 2021-03-08
CA3007990C (fr) 2024-01-02
WO2017100662A1 (fr) 2017-06-15
MX2018007075A (es) 2018-11-09
IL259863B (en) 2020-06-30
US20190276471A1 (en) 2019-09-12
KR102103395B1 (ko) 2020-04-23
HRP20201193T1 (hr) 2020-11-13
JP6835846B2 (ja) 2021-02-24
US20230097422A1 (en) 2023-03-30
US20170283430A1 (en) 2017-10-05
AR107042A1 (es) 2018-03-14
MD3386991T2 (ro) 2020-11-30
ME03803B (fr) 2021-04-20
CY1123263T1 (el) 2021-12-31
ES2805835T3 (es) 2021-02-15
CA3007990A1 (fr) 2017-06-15
UY37015A (es) 2017-06-30
US20210101910A1 (en) 2021-04-08
IL259863A (en) 2018-07-31
EP3386991B1 (fr) 2020-06-03
US10717745B2 (en) 2020-07-21
CN113121562B (zh) 2022-09-13
PT3386991T (pt) 2020-08-18
US11319329B2 (en) 2022-05-03

Similar Documents

Publication Publication Date Title
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
PH12018501463A1 (en) Pyrimidinyl tyrosine kinase inhibitors
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
EA201691514A1 (ru) Соединения
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39337B1 (fr) Modulateurs de pyrazines de gpr6
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MX2019000884A (es) Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton.
FR3078704B1 (fr) Derives d'isohexide et leurs utilisations
MA54520B1 (fr) Composés anticancéreux
EA201992728A1 (ru) Ингибиторы киназы и способы их применения